COVID-19 information and resources
Our latest COVID-19 updates
Throughout the COVID-19 pandemic, Mass General Brigham Health Plan was committed to ensuring timely access to high-quality healthcare services for our members. Following the end of the COVID-19 Public Health Emergency on May 11, 2023, this commitment remains a top priority. We have aligned our COVID-19 coverage policies based on public health recommendations and regulatory guidance.
Effective on May 12, 2023
-
Commercial members
COVID-19 tests and treatments* ordered by a provider, as well as COVID-19 vaccines will continue to be covered with no cost-sharing for members.
*As of 1/1/2024, cost sharing applies to COVID-19 related services for HSA qualified health plans.
Over-the-counter COVID-19 tests are no longer covered.
-
Mass General Brigham Accountable Care Organization (ACO) members
In alignment with MassHealth requirements, the following will continue to be covered at no cost:
- COVID-19 tests and treatments when ordered by a provider
- COVID-19 vaccines
- Two over-the-counter tests every 28 days
-
Medicare Advantage members
Medicare Advantage members can learn more about coverage for COVID-19 tests, treatments, and vaccines at Medicare.gov.
Information for providers
Please follow our standard policies and procedures as outlined in our provider resources or your contract. Our covered COVID-19 diagnosis codes are listed below.
-
COVID-19 diagnosis codes
Code Description U07.1 COVID-19 U09.9 Post COVID-19 condition, unspecified M35.81 Multisystem inflammatory syndrome Z01.81 Encounter for preprocedural examinations (please include 6th character for exam description) Z11.52 Encounter for screening for COVID-19 Z20.822 Contact with and (suspected) exposure to COVID-19
Covered diagnosis codes for COVID-19 evaluation and treatment- Evaluation for suspected Covid-19:
- Asymptomatic individuals with actual or suspected exposure to COVID-19 or for symptomatic individuals with actual or suspected exposure to COVID-19 and the infection has been ruled out, or test results are inconclusive or unknown:
- Facility claims use Z20.822 as the primary diagnosis
- Professional claims use Z20.822 pointed to the line for the related service
- Asymptomatic individuals with actual or suspected exposure to COVID-19 or for symptomatic individuals with actual or suspected exposure to COVID-19 and the infection has been ruled out, or test results are inconclusive or unknown:
- Confirmed diagnosis for Covid-19:
- Facility claims use U07.1 as the primary diagnosis
- Professional claims use U07.1 pointed to the line for the related service
- Multisystem Inflammatory Syndrome for individuals with multisystem inflammatory syndrome (MIS) and COVID-19:
- Facility claims use U07.1 as the primary diagnosis
- Professional claims U07.1 and M35.81 pointed to the claim line for the related service
- Multisystem Inflammatory Syndrome due to post Covid-19 condition
- For facility claims use U09.9 and M35.81 billed together
- For professional claims use U09.9 and M35.81 pointed to the line claim for the related service
- Patients receiving preoperative evaluations only:
- ICD-10-CM Coding Guidelines instruct to sequence first a code from subcategory Z01.81 (Encounter for preprocedural examinations)
- Evaluation for suspected Covid-19: